Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)

As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% seroconverted, with significantly lower seroconversion rates in those over 60 years (p = 0.004) and significantly low...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeewandara, Chandima, Fernando, Suranga, Pushpakumara, Pradeep Darshana, Ramu, Shyrar Tanussiya, Kamaladasa, Achala, Gunasekara, Banuri, Aberathna, Inoka Sepali, Kuruppu, Heshan, Ranasinghe, Thushali, Dayarathne, Shashika, Dissanayake, Osanda, Gamalath, Nayanathara, Ekanayake, Dinithi, Jayamali, Jewantha, Wijesinghe, Ayesha, Dissanayake, Madushika, Somathilake, Gayasha, Harvie, Michael, Danasekara, Saubhagya, Jayathilaka, Deshni, Wijayatilake, Helanka Dinesh Kumara, Weerasooriya, Nihal, Kekulandara, Chinthaka, Schimanski, Lisa, Rijal, Pramila, Tan, Tiong K., Dong, Tao, Townsend, Alain, Ogg, Graham S., Malavige, Gathsaurie Neelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810924/
https://www.ncbi.nlm.nih.gov/pubmed/35110645
http://dx.doi.org/10.1038/s41598-022-05788-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810924/
https://www.ncbi.nlm.nih.gov/pubmed/35110645
http://dx.doi.org/10.1038/s41598-022-05788-6

Ejemplares similares